In today’s briefing:
- EOFLOW/Medtronic Tender: Appeals Brief Is All Bark, No Bite
- Medikit (7749 JP) Below Market Tender Offer Buyback
- Orthofix International (OFIX US): Limited Downside Likely; Looking Ahead to 2024 with New Management
- China’s Ophthalmic Hospital Market – The Major Players, the Business Logic and the Outlook
- MariMed, Inc. – Begins Manufacturing and Processing in Illinois
- InMed Pharmaceuticals, Inc. – Expands Ocular Disease Treatment Pipeline
- Oryzon Genomics – Grant to bolster ALS pipeline, add funding
EOFLOW/Medtronic Tender: Appeals Brief Is All Bark, No Bite
- Eoflow (294090 KS) filed a 117-page appeal against the amended preliminary injunction (PI), sparking a 16% share price rally. Insulet Corp (PODD US) is required to respond by 14 December.
- Eoflow argues that the Massachusetts District Court committed legal errors. However, Eoflow’s arguments are rehashed from those that the district court has already dismissed with balanced counterarguments.
- The appeal is Eoflow’s last roll of the dice. Eoflow’s appeal brief worryingly notes that the PI profoundly imperils both the Medtronic transaction and its status as a going concern.
Medikit (7749 JP) Below Market Tender Offer Buyback
- Japanese medical products maker Medikit Co Ltd (7749 JP) Tuesday announced a buyback of ~12% of its shares from the founder’s company.
- The stock is extraordinarily illiquid. 12mo ADV is <US$40k/day. But Medikit runs 40% gross margins, 20% EBIT margins, and trades at an EV/revenue ratio of ~0.8x. It’s cash-rich, and cheap.
- But it’s an interesting situation. The buyback (and its reason) combined with the shareholder structure allow me to idly speculate this is an MBO candidate.
Orthofix International (OFIX US): Limited Downside Likely; Looking Ahead to 2024 with New Management
- In November, Orthofix International Nv (OFIX US) named Massimo Calafiore as incoming President and CEO. Mr. Calafiore has extensive knowledge in orthopedics and spine, and M&A integration expertise.
- Orthofix has performed well and operated smoothly following management transition. In 3Q23, revenue increased 61% YoY on a reported basis and 1% YoY on a pro forma basis to $184M.
- The company expects to deliver much higher adjusted profits next year and to exit 2024 cash-flow positive from an estimated $100 million outflow for 2023.
China’s Ophthalmic Hospital Market – The Major Players, the Business Logic and the Outlook
- Against the backdrop of China’s reopen after the pandemic is under control, the performance comparison of the four major ophthalmic hospitals in the A-share market has attracted investors’ attention.
- Aier Eye Hospital is already going downhill. Bright Eye Hospital leads Huaxia Eye Hospital in national layout/growth rate. He Eye Hospital has a big gap compared to the rest three.
- The “weaknesses” of Huaxia and He Eye Hospital in business layout isn’t obvious currently.But in good times, the impact of businesses with strong consumption attributes on performance would be amplified.
MariMed, Inc. – Begins Manufacturing and Processing in Illinois
- MariMed has begun manufacturing and processing cannabis products in its new kitchen in Mount Vernon, Illinois.
- As often happens in cannabis, there were construction and regulatory delays, but the company expects to have its award-winning edibles in Illinois stores in time for the holidays.
- Illinois is the sixth-most populated state with 12.7 million residents.
InMed Pharmaceuticals, Inc. – Expands Ocular Disease Treatment Pipeline
- Unveiling INM-089 targeting AMD. InMed is expanding its rare cannabinoid cannabinol (CBN)-based ocular disease treatment pipeline with INM-089, targeting age- related macular degeneration (AMD).
- INM-089, a CBN analog, is InMed’s second ocular pharmaceutical program, with the company currently engaged in pre-clinical studies of INM-088, investigating its effects in the treatment of glaucoma.
- InMed’s ocular programs target leading causes of severe eyesight loss and blindness.
Oryzon Genomics – Grant to bolster ALS pipeline, add funding
Oryzon has announced the receipt of a $0.5m grant from the Amyotrophic Lateral Sclerosis (ALS) Association to support the regulatory clinical development of the company’s histone deacetylase 6 (HDAC6) inhibitor, ORY-4001, as a potential treatment for ALS. We view this as a favourable advancement that enables the company to expand its preclinical pipeline. This news of this funding grant follows on the heels of Oryzon’s recently announced €45m convertible financing arrangement. Oryzon plans to progress ORY-4001 through various investigational new drug (IND)-enabling studies and we anticipate updates from the company as the data become available. The most significant upcoming catalyst for Oryzon is top-line readouts for the Phase IIb PORTICO trial for lead clinical asset vafidemstat for the treatment of borderline personality disorder, expected in Q124.